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Objective: Themicro RNAs (miRNAs) and their target mRNAs are differentially expressed in
various immune-mediated cells. Here, we investigated the role ofMir223 and sphingosine-
1-phosphate receptor 1 (S1pr1) in the pathogenesis of systemic lupus erythematosus.
Methods: We analyzed miRNA and mRNA profiling data of CD4+ splenic T cells derived
from MRL/MpJ-Faslpr/J mice. We performed 3′ untranslated region (UTR) luciferase
reporter gene assay using human umbilical vein endothelial cells (HUVECs). We
generated the B6-Mir223−/−Faslpr/lpr mice and the lupus phenotypes were analyzed.
Results: In CD4+ splenic T cells, we identified upregulation of miR-223-3p and
downregulation of the possible target, S1pr1 by RNA sequencing of MRL/MpJ-Faslpr/J
mice. The transfection with miR-223-3p mimic significantly suppressed a luciferase
activity in HUVEC treated with a Lentivirus vector containing 3′ UTR of S1pr1. The
mRNA levels of S1pr1 were significantly decreased after miR-223-3p overexpression. In
B6-Mir223−/−Faslpr/lpr mice, the proportion of CD3+ T cells, CD3+CD4-CD8− cells, B cells,
plasma cells, and S1PR1+CD4+ T cells in the spleen was significantly increased compared
with that in B6-Mir223+/+Faslpr/lpr mice by flow cytometry. B6-Mir223−/−Faslpr/lpr mice
demonstrated the elevation of glomerular and renal vascular scores associated with
enhanced intraglomerular infiltration of S1PR1+CD4+ T cells.
Conclusion: Unexpectedly, the deletion of Mir223 exacerbated the lupus phenotypes
associated with increased population of S1PR1+CD4+ T in spleen and the enhanced
infiltration of S1PR1+CD4+ T cells in inflamed kidney tissues, suggesting compensatory
role of Mir223 in the pathogenesis of lupus nephritis.
Keywords: miR-223-3p, S1pr1, S1PR1+CD4+ T cells, lupus nephritis, MRL/MpJ-Faslpr/J miceorg January 2021 | Volume 11 | Article 6161411
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Systemic lupus erythematosus (SLE) is a chronic autoimmune
disease associated with the overproduction of autoantibodies and
infiltration of autoreactive B and T lymphocytes in lymphoid and
non-lymphoid organs. Despite therapeutic advancements, the
improvement of mortality or the development of end-stage renal
disease has not been demonstrated and the development for new
effective and targeted drugs is urgently required (1). Genetic,
environmental, hormonal, epigenetic, and immunoregulatory
factors are associated with the pathogenesis of SLE (2). DNA
methylation, histone modification, and altered micro RNA
(miRNA) are widely recognized as the key epigenetic
mechanisms. miRNAs target specific mRNAs for mRNA
stability and can fine-tune the expression of multiple mRNAs.
In the patients with SLE andMRL/MpJ-Faslpr/J (MRL/lpr) lupus-
prone mice, several identified miRNAs affect the central pathway
of SLE (3); for instance, upregulated miR-21 regulates
lymphocyte signaling (4) and miR-155 deficiency which
suppresses lupus activity by targeting sphingosine 1-phosphate
(S1P) receptor 1 (S1pr1) (5). We previously performed global
miRNA and mRNA profiling in CD4+ T cells purified from the
spleen of MRL/lpr mice and compared with the C57BL6/J (B6).
We identified miR-200a-3p and reported that it is involved in the
hypoproduction of IL-2 in T cells by targeting CtBP2 complex in
MRL/lpr mice (6). Therefore, the study of the role of miRNAs
may provide important clues for potential future therapies in
SLE patients.
In the present study, we investigated the roles of miR-223-3p
and S1pr1 mRNA in the MRL/lpr lupus-prone mice. Mir223 is
highly expressed and tightly regulated in hematopoietic cells,
especially myeloid cells, for controlling excessive innate immune
responses (7). Mir223 in CD4+ T cells inhibit the human
immunodeficiency virus (HIV) activity by targeting 3′ end of
HIV genome (8). In autoimmune diseases, upregulation of
Mir223 in peripheral CD4+ T cells, especially Th17, has a
potential role in progression of multiple sclerosis (9). In SLE
patients, Mir223 has been only explored as immunological
biomarkers for disease pathophysiology. Although upregulation
of Mir223 in peripheral plasma was reported (10, 11), the
expression of Mir223 in peripheral plasma was significantly
decreased in SLE patients with active nephritis (12).
S1pr1 has been known to be expressed in several cell types of
the immune system. Especially, S1PR1 on T cells plays a pivotal
role in T cell circulation among secondary lymphoid organs
dependent on S1P concentration (13–15). S1pr1 conventional
knockout mice exhibited intrauterine death by incomplete
vascular maturation (16). T cell-specific S1pr1 knockout mice
showed a block in the egress of T cell from thymus into circulation
and a reduction of lymphocytes, especially CD3+ cells, in
secondary lymphoid organs (13). The S1P and S1PR1 signaling
in T cells is also essential for T cell survival (17). The S1pr1
expression of peripheral blood mononuclear cells was decreased in
SLE patients and B6.MRL-Faslpr mice (5). Agonists of S1PR1
suppressed the development of autoimmunity and renal injury by
inducing sequestration of peripheral lymphocytes including
autoreactive T cells into secondary lymphoid organs, reducingFrontiers in Immunology | www.frontiersin.org 2their infiltrates in target organs, and inducing its apoptosis in
MRL/lpr mice (18–23). As mentioned above, miR-155 knockout
lupus-prone B6.MRL-Faslpr mice showed milder SLE clinical
features than B6.MRL-Faslpr mice by targeting S1pr1 (5).
Although the role of S1pr1 in SLE is not completely understood,
the miRNAs regulating the expression of S1pr1 are expected
critically involved in the pathogenesis of SLE. Here, we
demonstrated that miR-223-3p plays a critical role in the
regulation of T cell circulation and apoptosis by targeting S1PR1
in lupus prone mouse. The current investigation provides new
data on the epigenetic control of T cell circulation in SLE.MATERIALS AND METHODS
Mice
B6.Cg-PtprcaMir223tm1Fcam/J (referred to as B6-Mir223−/−Ptprca/a)
on background of C57BL/6J (Ptprca) (24), genetically lupus-prone
female MRL/MpJ-Faslpr/J (referred as MRL/lpr or MRL-Faslpr/
lprPtprcb/b), B6.MRL-Faslpr/J (referred to as B6/lpr or B6-Faslpr/
lprPtprcb/b) on background of C57BL/6J (Ptprcb) (Jackson
Laboratory), and C57BL/6J (Ptprcb) (referred as B6) (Charles
River Laboratories) were purchased. The Mir223 gene is located
on the X chromosome. The animals were maintained in a 12-h
light/dark cycle, with free access to water and standard rodent chow.
The following animal experiments were approved by the Animal
Care and Use Committee of the Department of Animal Resources,
Advanced Science Research Center, Okayama University under the
approval numbers of OKU-2013092, OKU-2015569, OKU-
2015658, OKU-2015661, OKU-2015662, OKU-2015663, OKU-
2015664, OKU-2016191, OKU-2016192, OKU-2016365,
OKU-2016383, OKU-2016384, OKU-2016385, OKU-2017499,
OKU-2017500, OKU-2017501, OKU-2017502, OKU-
2018474, OKU-2018475, OKU-2018582, OKU-2018583, OKU-
2018583, and OKU-2018585. All animal experiments were
performed in accordance with relevant guidelines and regulations.
mRNA and miRNA Expression Profiling
by RNA Sequencing
Total RNA, including miRNA, was purified from CD4+ T cells of
MRL/lpr mice and B6 mice using a miRNeasy mini kit (Qiagen).
mRNA and miRNA sequencing and expression profile data were
prepared as previously described (6). All raw and processed
data are freely accessible in the Gene Expression Omnibus
(https://www.ncbi.nlm.nih.gov/geo/) under the accession
number GSE87219.
3′ Untranslated Region Luciferase
Reporter Gene Assay
Human Umbilical Vein Endothelial Cells (HUVECs; CC-2519,
Lonza) were cultured in EGM-2 medium (CC-3162, Lonza)
supplemented with 10% fetal bovine serum (FBS) in a
humidified atmosphere containing 5% CO2 at 37°C. The
culture medium was replaced every 1–2 days, cells at 85–90%
confluence were passaged at a ratio of 1:3 confluence. The cells
were used between passages two and five in the followingJanuary 2021 | Volume 11 | Article 616141
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of S1PR1 (HUTR09173; S1PR1-3′UTR) and MISSION 3′UTR
Lenti GoClone-Controls (HUTR001C-004C; Controls) were
purchased from Sigma-Aldrich. The Lentivirus particles and
8 mg/ml Hexadimethrine bromide® (H9268, Sigma-Aldrich)
were added to HUVECs for 10 h and then replaced with fresh
medium. After 24 h, the infected cells were subjected to selection
with 0.25 mg/ml puromycin. The selected cells were further co-
transfected with miR-223-3p mimic and its negative control
(nontargeting miRNA) into HUVECs using RNAiMAX
(Invitrogen). The cells were harvested after 24 h of
transfection, and Renilla luciferase activity was measured using
the Luciferase Reporter Assay System Kit (MLS0001, Sigma-
Aldrich) and GloMax® 20/20 Luminometer (Promega).
Evaluation of Active and Chronic Lesions
of Lupus Nephritis
For histology, mouse kidneys were fixed in 10% formalin for 24 h
at 4°C, and 4 mm paraffin sections were stained with hematoxylin
and eosin, periodic acid-Schiff (PAS) stain. Glomerular
hypercellularity was evaluated by counting the number of
nuclei per glomerular cross-section in 10 randomly selected
glomerular cross-sections per mouse. The glomerular lesions
were graded on a scale of 0–3 as previously described (25). The
glomerular lesion index was calculated from the sum of the
scores for 40 randomly selected glomerular cross-sections per
mouse. Renal vascular lesions were graded on a scale of 0–3 as
previously described (25). The vascular lesion index was
calculated from the sum of the scores for all vessels per
section. Tubulointerstitial lesions were graded on a scale of 0–4
as previously described (26). The tubulointerstitial lesion index
was calculated from the sum of the scores for 30 consecutive
high-power fields (HPF) at a magnification of ×400 in the cortex
per section.
Immunofluorescence
Mouse kidneys were immediately frozen at −80°C in OCT
compound (Sakura, Japan), and 4 mm cryostat sections were
stained with fluorescein isothiocyanate (FITC) conjugated goat
anti-mouse IgG or rabbit anti-mouse C3 (Cappel). Staining of all
sections was visualized with a fluorescence microscope (BX51;
Olympus). Immunofluorescence intensity (measured as the
number of pixels/µm2) was quantified using cellSens software
(version 1.16; Olympus). At least five glomeruli per section
were analyzed.
For immunofluorescence with CD4, CD8, and S1PR1, mouse
kidneys were embedded in OCT compound (Sakura, Japan), and
4 mm cryostat sections were fixed in 4% paraformaldehyde
(PFA). After blocking in 5% BSA, the sections were incubated
with the appropriate primary antibodies; rat monoclonal anti-
CD4 (1:50; RM4-5, 100505), rat monoclonal anti-CD8a (1:50;
53-6.7, 100701) (BioLegend), and rabbit polyclonal S1PR1(1:100;
ab137467, Abcam). After overnight incubation, the sections were
further treated with Alexa Fluor® 647 conjugated goat anti-rat
secondary antibody (ab150167, Abcam) or Alexa Fluor® 594
conjugated goat anti-rabbit secondary antibody (ab150084,Frontiers in Immunology | www.frontiersin.org 3Abcam). Nuclear staining was performed using 4′,6-diamidino-
2-phenylindole (DAPI; 422801, BioLegend). Staining of all
sections was visualized with a fluorescence microscope (BZ-
X700; Keyence). Quantitation of staining was graded based on
the number of positive cells per glomerulus or per HPF for
tubular infiltrates, with a minimum of 10 glomeruli of HPF per
mouse examined.
RNA Isolation and Real-Time RT-PCR
Total cellular RNAs from human and mouse samples were
extracted with an RNeasy mini kit (Qiagen). cDNAs were
reverse transcribed from mRNAs with a high-capacity cDNA
RT kit (Thermo Fisher Scientific), while cDNAs from miRNAs
with a TaqMan miRNA reverse transcription kit (Thermo Fisher
Scientific). Real-time PCRs for miR-223-3p (002295), sno-202
(001232), sno-234 (001234) and RNU48 (001006) were
performed using TaqMan primer/probes with TaqMan miRNA
assays (Thermo Fisher Scientific). The expression of miRNAs
was normalized to sno-202 and sno-234 for mice and RNU48 for
human samples by the DDCt method. Real-time PCRs for
S1pr1 (Mm02619656_s1), Gapdh (Mm99999915_g1),
Cxcl9 (Mm00434946_m1), Cxcl10 (Mm00445235_m1), Cxcl11
(Mm00444662_m1), Ccl2 (Mm00441242_m1) , Ccl4
(Mm00443111_m1), Ccl5 (Mm01302427_m1), S1PR1
(Hs01922614_s1) and GAPDH (Hs02786624_g1) were
performed using ABI TaqMan gene expression assays (Applied
Biosystems) according to the manufacturer’s protocol and
normalized to GAPDH by the DDCt method.
Systemic Lupus Erythematosus Patients
and CD4+ T Lymphocyte Purification
The 15 SLE patients (10 females and five males) who fulfilled at
least four of the 11 revised criteria of the American College of
Rheumatology for the classification of SLE and 6 healthy controls
were enrolled and peripheral CD4+ T lymphocytes were purified
as previously described (27). The studies were approved by the
Ethical Committee, Okayama University Hospital (#1779) and
the written informed consent was obtained.
Statistical Analyses
All results are shown as the mean ± standard error (SE) of data
from at least three separate experiments, each performed with
more than triplicate samples. Normal distribution of the data was
assessed by Shapiro–Wilk test, and statistically significant
differences between groups were determined using the
Student’s 2-tailed t-test or Wilcoxon signed-rank test, as
appropriate. The data were also analyzed with one-way
analysis of variance and Tukey’s honestly significant difference
test when multiple comparisons against the control were
required. Pearson’s c2 test was used to compare the
distribution of glomerular lesions with grading scores from 0
to 3 (25), renal vascular lesions with grading scores from 0 to 3
(25) and tublointerstitial injury with grading scores from 0 to 4
(26). P values less than 0.05 were considered significant. All
statistical analyses were performed using the JMP 11.2.0 software
package (SAS Institute).January 2021 | Volume 11 | Article 616141
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Upregulated miR-223-3p and Repressed
S1pr1 mRNA Levels in CD4+ T Cells of
MRL/lpr Mice
To identify new candidate miRNAs and their target mRNAs
involved in the pathogenesis of SLE, we integrated miRNA and
mRNA sequencing data in splenic CD4+ T cells isolated fromMRL/
lpr and B6 mice (GSE87219). A total of 19 miRNAs were
upregulated in MRL/lpr compared with B6 mice with a cut-off
value of >10-fold (Figure 1A and Supplementary Table 1). We
further screened the sets of upregulated miRNA and >2-fold
downregulated mRNAs, which were retrieved from miRDB
(http://mirdb.org.) as predicted targets. Among them, we
identified that upregulation of miR-223-3p was associated with
downregulation of 23 mRNAs by RNA sequencing data (Figure 1B
and Supplementary Table 2). We further investigated the
downregulation of predicted (S1pr1) target mRNAs in MRL/lpr,
B6/lpr and B6mice. By quantitative real-time PCR,miR-223-3p was
upregulated and S1pr1 was most significantly downregulated in
MRL/lpr and B6/lpr mice compared with B6 mice (Figures 1C, D).
Although the mRNA levels of S1pr1 were significantly decreased in
splenic CD4+ T cells from MRL/lpr compared with those from B6,
the protein levels of S1PR1 were rather increased in splenic CD4+ T
cells from MRL/lpr compared with those from B6 (Supplementary
Figure 1A). S1PR1 protein expression on surface of CD4+ T cells is
known to be downregulated in the blood and upregulated in
lymphoid organ (28). It was reported that S1P induces S1PR1Frontiers in Immunology | www.frontiersin.org 4internalization via endosomal pathway (29), and it subsequently
undergoes ubiquitylation and proteasomal degradation by the
ubiquitin ligase WW domain containing E3 ubiquitin protein
ligase 2 (Wwp2) (30, 31). The S1PR1 protein was supposed to be
regulated by posttranslational modification inMRL/lpr mice and we
further examined ubiquitination of S1PR1 protein in splenic CD4+
T cells from MRL/lpr and B6. The starting materials (SMs)
demonstrated higher expression of S1PR1 protein in CD4+ T cells
fromMRL/lpr compared with B6, while it was barely detected in the
eluted fractions (ELs) of highly purified ubiquitinated proteins by
UbiQapture-Q Kit (Supplementary Figure 1B). Taken together,
upregulation of S1PR1 protein in splenic CD4+ T cells from
MRL/lpr was mediated by reduced ubiquitination of the S1PR1,
although B6 was not an appropriate control for MRL/lpr.
As shown in Supplementary Table 3, the 3′UTR region of
S1pr1 was predicted to serve as binding site for miR-223-3p in
humans and mice. To determine whether S1pr1 was a direct
target of miR-223-3p, Lentivirus of S1pr1-3′UTR and Controls
were infected to HUVECs for luciferase miRNA target assays.
Co-transfection of miR-223-3p mimic demonstrated a
significant reduction in luciferase activity, while nontargeting
miRNA did not alter the luciferase activity (Figure 2A). To
further confirm that S1pr1 is a target of miR-223-3p, we detected
the endogenous S1pr1 mRNA and protein level after transiently
transfecting mimic miR-223-3p into EL4 cells. As shown in
Figure 2B, the expression level of S1pr1 mRNA and protein
decreased after miR-223-3p overexpression. Taken together, the
miR-223-3p is a negative regulator for S1pr1.A
B D
C
FIGURE 1 | Top 20 differential expression levels of miRNAs and mRNAs in CD4+T cells isolated from MRL/lpr lupus-prone (MRL/lpr) vs C57BL/6 (B6) mice by
microarray analysis. (A) Fold change (ratio between MRL/lpr/B6) in miRNA expression MRL/lpr vs B6. We focused on mmu-miR-223-3p which was indicated by
arrow. (B) Candidate target genes for upregulated mmu-miR-223-3p were identified using the commonly used prediction algorithm, miRDB. These targets and our
mRNA expression profiles were integrated. Fold change (ratio between MRL/lpr/B6) in mRNA expression MRL/lpr vs B6. We focused on S1pr1 which was indicated
by arrow. (C) The expression level of miR-223-3p was evaluated by TaqMan quantitative PCR in MRL/lpr mice and B6/lpr lupus-prone (B6/lpr) mice compared with
B6 mice (n = 5 per group, 16-week-old female). (D) The expression of S1pr1 in CD4+T cells of mice spleen was evaluated by TaqMan quantitative PCR (n =5 per
group, 16-week-old female). Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, by Student’s t-test.January 2021 | Volume 11 | Article 616141
Hiramatsu-Asano et al. Mir223 and S1pr1 in Lupus NephritisReduction of S1PR1 mRNA in CD4+ T Cells
From the Patients With Systemic Lupus
Erythematosus
We investigated the expression levels of S1PR1mRNA and miR-
223-3p in circulating CD4+ T cells isolated from SLE patients and
healthy subjects. The demographics of the enrolled SLE patients
are shown in Supplementary Table 4. The patients with SLE also
showed similar trends like MRL/lpr mice; the expression level of
S1PR1 mRNAs in CD4+ T cells is significantly downregulated in
SLE patients than healthy control, while miR-223-3p tended to
upregulate in SLE patients without statistical differences (Figure
3A). Given the critical role of S1PR1 mRNA and miR-223-3p in
SLE, we investigated the simple correlations with clinical
parameters (Supplementary Table 4). miR-223-3p expression
levels in SLE patients with skin disorders, such as malar rash,
were significantly lower than SLE patients without skin
symptoms. However, in the SLE patients with lung disorders,
such as pleural effusion, miR-223-3p expression level was
significantly higher than SLE patients without lung symptoms
(Figure 3B). S1PR1 mRNA expression level in SLE patients with
skin disorder was significantly higher than SLE patients without
skin involvement, while it was lower in the SLE patients with
central nervous system (CNS) involvement compared with SLE
patients without this manifestation (Figure 3C). These results
indicated that miR-223-3p upregulation linked to S1PR1 mRNA
downregulation in SLE, in patients with skin involvements.
Systemic Lupus Erythematosus
Phenotypes in Mir223−/−Faslpr/lpr Mice
To explore the involvement of miR-223-3p in the pathogenesis of
SLE, we generated B6-Mir223−/−Faslpr/lpr mice. We observed B6-
Mir223−/−Faslpr/lpr and B6-Mir223+/+Faslpr/lpr mice until 44
weeks of age and found that there were no differences in body
weight, survival rate, skin score, organ weight, total cell numbers
in spleen and lymph nodes, and circulating blood cell counts
between two groups (Supplementary Figures 2A–F). TheFrontiers in Immunology | www.frontiersin.org 5significant gain of weight was reported in B6-Mir223−/−Ptprca/a
compared to C57BL/6J (Ptprca) (32) and the number of
circulating neutrophils in Mir223 knockout mice significantly
increase and spontaneously develop lung inflammation marked
by neutrophil infiltration (24). However, the presence of Faslpr/lpr
in mice canceled such MiR223 deficiency-induced phenotypes.
Similarly, in MRL/lpr background, no differences were observed
in body weight, survival rate, skin score, organ weight, and total
cell numbers in spleen and lymph nodes between MRL-
Mir223− /−Faslpr/ lpr and MRL-Mir223+/+Faslpr/ lpr mice
(Supplementary Figures 3A–E). Serum levels of total IgG and
anti- dsDNA antibody were not altered in B6-Mir223−/−Faslpr/lpr
and B6-Mir223+/+Faslpr/lpr (Supplementary Figure 2G). We
further examined the serum levels of immunoglobulin
subclasses (IgA, IgM, IgG1, IgG2b, IgG2c, and IgG3).
Although IgG2b levels at 44 weeks of age significantly elevated
in B6-Mir223−/−Faslpr/lpr, rest of them demonstrated no
significant increase (Supplementary Figure 2G). Similarly,
there were no differences in gamma globulin and autoantibody
production between MRL-Mir223−/−Faslpr/lpr and MRL-Mir223+/+
Faslpr/lpr mice (Supplementary Figure 3F).
Changes in Lymphocyte Population
in Spleen and Lymph Nodes From
Mir223−/−Faslpr/lpr Mice
MRL/lpr mice are characterized by increased numbers of
activated CD4+ T cells, CD3+CD4−CD8− cells (double-negative
T cells; DNT), B cells, and plasma cells as compared with B6 (33,
34). We next investigated the cell population in spleen and
lymph nodes by flow cytometry. The proportion of CD4+ and
CD8+ T cells, memory and effector T cells, and activated CD4+
(CD69+CD4+) T cells in both spleen and lymph nodes did not
differ between B6-Mir223−/−Faslpr/lpr and B6-Mir223+/+Faslpr/lpr
mice (Figure 4A). Compared with B6-Mir223+/+Faslpr/lpr mice,
B6-Mir223−/−Faslpr/lpr showed a significantly higher proportion
of CD3+ T cells, DNT cells, B cells, and plasma cells in the spleenA B
FIGURE 2 | The miR-223-3p is a negative regulator for S1pr1. (A) HUVECs were co-transfected with nontargeting miRNA and miR-223-3p mimic with the no UTR
or 3′UTR. Luciferase activity was assayed 24 h after transient co-transfection. Renilla luciferase activity was measured. (n = 3 per group). Data are presented as
mean ± SEM. *p < 0.05, ns, not significant, by Wilcoxon signed-rank test. (B) The mRNA and protein level of S1pr1 in EL4 cells was analyzed by TaqMan
quantitative PCR and Western blot analyses after transfection with miR-223-3p mimic or nontargeting miRNA. The transfection efficacy of miR-223-3p mimic was
confirmed by TaqMan quantitative PCR. miR-223-3p was transfected by lipofection, and the expression was compared with the nontargeting miRNA after 24 h
transfection. The mRNA and protein levels of S1pr1 after the overexpression of miR-223-3p was confirmed by TaqMan quantitative PCR and Western blot analyses.
Numbers above the Western blots indicate band intensity (normalized to total GAPDH) measured by using ImageJ software. Quantification of Western blot results
(right side). (n = 3 per group). Data are presented as mean ± SEM. *p < 0.05, ns, not significant, by Wilcoxon signed-rank test.January 2021 | Volume 11 | Article 616141
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the spleen increased in B6-Mir223−/−Faslpr/lpr mouse (Figure
4A), suggesting Mir223 deficiency contributed to the increased
cell surface expression of S1PR1. The low S1P concentration in
secondary lymphoid organs and relatively higher concentrations
in lymphatic fluid promotes S1PR1-dependent movement of T
cells from secondary lymphoid organs back into the lymphatic
circulation and then into blood (35). Next, we measured the
concentration of S1P in B6-Mir223−/−Faslpr/lpr and B6-Mir223+/+
Faslpr/lpr mice; however, there were no significant differences
between two genotypes (Supplementary Figure 2G), suggesting
that surfaced S1PR1 on splenic T cells throughMir223 deficiency
may promote to egress from lymphoid organ to blood and
infiltrate to inflamed tissue. In contrast, there were no
differences in T and B cell populations in the spleen and
lymph nodes between Mir223 knockout lupus-prone MRL-
Mir223− /−Faslpr/ lpr and MRL-Mir223+/+Faslpr/ lpr mice
(Supplementary Figure 3E and Supplementary Figure 5E).Frontiers in Immunology | www.frontiersin.org 6Gene Expression and Apoptosis in CD4+
and CD8+ T Cells From Spleen and Lymph
Nodes of Mir223−/−Faslpr/lpr Mice
The impairment of apoptosis due to Fas mutation is one of the
mechanisms underlying the pathogenesis of Faslpr/lpr mice.
Therefore, the induction of apoptosis has been reported to
ameliorate the clinical features in the mice (36). MRL/lpr mice
treated with a selective agonist of S1PR1 (KRP-203) showed
enhancement of lymphocytes apoptosis in lymph nodes and
reduction of T cell infiltrates in kidney (23). We further examined
whether apoptosis is enhanced in the lymph nodes ofA
B
C
FIGURE 3 | The decreased level of S1PR1 and increased level of miR-223-
3p transcripts in CD4+ T cells from SLE patients. (A) mRNA expression of
S1PR1 and miR-223-3p in CD4+ T cells isolated from healthy (n = 6) and the
patients with SLE (n = 15). Data are presented as mean ± SEM. *p < 0.05,
ns, not significant, by Wilcoxon signed-rank test. (B, C) The miR-223-3p and
S1PR1 transcript level in CD4+ T cells isolated from the SLE patients with
organ involvement and no involvement. SLE patients with skin involvement
(n = 11) and without involvement (n = 4), with lung involvement (n = 2) and
without involvement (n = 13), with central nervous system involvement (n = 4)
and without involvement (n = 11), with kidney involvement (n = 6) and without
involvement (n = 9), with joints involvement (n = 10) and no involvement (n =
5). Data are presented as mean ± SEM. *p < 0.05, ns, not significant, by
Student’s t-test.A
B
FIGURE 4 | The proportion of CD3+ T cells, CD3+CD4-CD8- T cells, CD19+
B cells, CD19-CD138+ cells (Plasma cells), CD3+S1PR1+ T cells and
CD3+CD4+S1PR1+ T cells in spleen and early apoptotic cells in CD4+ and
CD8+ T cells in lymph nodes were significantly increased in B6-
Mir223−/−Faslpr/lpr mice. (A) Various cellular subsets in lymph nodes and
spleen. CD3+CD4+ (CD4 T cells), CD3+CD8+ (CD8 T cells), CD3+ CD4−CD8−
(Double negative (DN) T cells), CD19+ (B cells), CD19−CD138+ (Plasma cells),
CD19+CD138+ (Plasmablasts), CD4+CD44+CD62L+ (Memory T cells),
CD4+CD44+CD62L− (Effector T cells), CD69+CD4+ cells, S1PR1+CD3+ cells,
S1PR1+CD4+ cells. Distribution of subsets in total cells isolated from whole
cervical lymph nodes and spleen were indicated in B6-Mir223−/−Faslpr/lpr (n=7)
and B6-Mir223+/+Faslpr/lpr (n = 8) mice. Absolute number of total splenocyte
and lymph nodes cell had no difference between two genotypes
(Supplementary Figure 2E). (B) Apoptotic cells in lymph nodes and spleen.
Annexin V+7-AAD− (Early apoptosis cells), Annexin V+7-AAD+ (Late apoptotic
cells). Distribution of subsets in CD3+CD4+ T cells or CD3+CD8+ T cells
isolated from whole cervical lymph nodes and spleen were indicated in B6-
Mir223−/−Faslpr/lpr (n = 3) and B6-Mir223+/+Faslpr/lpr (n = 3) mice. *p < 0.05,
**p < 0.01, ns, not significant, by Student’s t-test in (A), by Wilcoxon signed-
rank test in (B).January 2021 | Volume 11 | Article 616141
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V+ and late apoptotic cells were unaltered, the elevated rate of early
apoptotic (Annexin V+ and 7-AAD−) CD4+ and CD8+ T cells in the
lymph nodes of B6-Mir223−/−Faslpr/lpr (Figure 4B) and MRL-
Mir223−/−Faslpr/lpr mice were observed (Supplementary Figure
5B). However, anti-apoptotic Bcl-2, Bcl-xL, and proapoptotic
Caspase-3 protein expression levels in lymph nodes and spleen
were not altered by the deficiency of Mir223 (Supplementary
Figure 4 and Supplementary Figure 5C). Since the ratio of late
apoptotic CD4 T cells and the cleavage of caspase-3 was not altered,
the promotion of whole apoptosis process was not confirmed as the
mechanisms to explain the phenotypes in B6-Mir223−/−Faslpr/lpr and
MRL-Mir223−/−Faslpr/lpr mice.
AlthoughmiR-223-3p in CD4+ and CD8+ T cells and B cells was
barely detected in the lymph nodes and spleens of B6-
Mir223−/−Faslpr/lpr mice (Supplementary Figure 6B), the S1pr1
mRNA and protein expression in CD4+ T cells from spleen and
lymph nodes were not altered in B6-Mir223−/−Faslpr/lpr compared
with that in B6-Mir223+/+Faslpr/lpr mice (Supplementary Figures
6A, C). The increased population of S1PR1+CD4+ cells in spleen in
B6-Mir223−/−Faslpr/lpr suggested that S1PR1+CD4+ T cells induced
by Mir223 deficiency may migrate from lymphatic tissues to non-
lymphatic inflamed tissues.
Exacerbation of Lupus Nephritis in
Mir223−/−Faslpr/lpr Mice
Immune complex glomerulonephritis is the hallmark of the non-
lymphatic tissue inflammation in MRL/lpr mice and human SLEFrontiers in Immunology | www.frontiersin.org 7patients (30, 37). In light microscopic examination of the tissue
sections, an exacerbation of histologic damage in B6-
Mir223−/−Faslpr/lpr mice was evidenced by an expansion in
glomerular size, increased cellularity, and kidney weight
(Figure 5A, Supplementary Figures 7C and 8B), although
mesangial matrix area demonstrated no significant difference
between two genotypes (Supplementary Figure 7C). The
distribution of glomerular and renal vascular lesions with
grading scores in B6-Mir223−/−Faslpr/lpr mice significantly
exacerbated (Figure 5B). Immunofluorescence study showed
S1PR1+CD4+ T cells in glomerular lesion and CD4+ T cells in
interstitial fibrosis lesion were significantly increased in B6-
Mir223−/−Faslpr/lpr compared to B6-Mir223+/+Faslpr/lpr mice
(Figures 6A, B, Supplementary Figure 8C). We also assessed
the effect of Mir223 deficiency on glomerular immune complex
formation/deposition. We found an enhanced deposition of C3
in the glomerular immune complex in B6-Mir223−/−Faslpr/lpr
mice compared to B6-Mir223+/+Faslpr/ lpr l ittermates
(Supplementary Figures 7A, B) and the deposition of IgG
demonstrated no significant changes (Supplementary Figure
7B). The tendency for the increase of S1PR1+CD4+ T cells in
glomerular lesions and CD4+ T cells in interstitial fibrosis lesions
was seen in MRL-Mir223−/−Faslpr/lpr mice (Supplementary
Figures 9 and 10). The daily urinary protein excretions tended
to be higher in B6-Mir223−/−Faslpr/lpr than B6-Mir223+/+Faslpr/lpr
mice (Supplementary Figure 8A).
Chemokines contribute to renal damage by recruiting
inflammatory cells to the kidney. The CXCR3 ligands, CXCL9A B
FIGURE 5 | Exacerbation of lupus nephritis in B6-Mir223−/−Faslpr/lpr mice. (A) Representative kidney sections from B6-Mir223−/−Faslpr/lpr and B6-Mir223+/+Faslpr/lpr
mice, stained with periodic acid–Schiff (PAS). Bars = 50 µm. (B) Score distribution of glomerular, renal vascular and tubulointerstitial lesions in B6-Mir223−/−Faslpr/lpr
compared to B6-Mir223+/+Faslpr/lpr mice (n = 10 per group). Data are presented as mean ± SEM. ***p < 0.001, ns, not significant, by Pearson’s c2 test in (B).January 2021 | Volume 11 | Article 616141
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the spleen and CCL-2, CCL4, CCL5, CXCL10 in nephritic
kidneys of Faslpr/lpr mice (38–41). T cell migration from blood
into tissue is induced by chemokines CXCL9 and CXCL11
presented on the endothelial surface, which activates surface
expression of S1PR1 and S1PR4 on T cells (42). The increased
S1P present in inflamed peripheral tissues may further induce T
cell retention. Therefore, we next evaluated the chemokine
mRNA levels in renal cortex. In both B6 and MRL/lpr mice,
Cxcl10, Cxcl11 and Ccl2 demonstrated higher mRNA levels in
Mir223−/−Faslpr/lpr compared withMir223+/+Faslpr/lpr; however, it
did not reach statistical differences (Supplementary Figures 8D
and 11). Although Cxcl10 was one of the predicted target
mRNAs of miR-223-3p from miRDB (http://mirdb.org.), the
roles of chemokines in infiltration of S1PR1+CD4+ T cells in
Mir223−/−Faslpr/lp may be limited.
Taken together, Mir223 deficiency can exacerbate the
functional and pathologic damage to the kidneys in B6-MRL-
Faslpr mice by facilitating the infiltration of S1PR1+CD4+ T cells
in both glomerular and interstitial lesions.DISCUSSION
Recent studies have demonstrated that miRNAs play important
roles in the pathogenesis of SLE (3). In pristine-induced lupus mice,
lupus nephritis is ameliorated by miR-654 mimic injection therapy
(43). Mir155 knockout mice demonstrated the amelioration of
autoimmune inflammation (5). miRNAs themselves might
become therapeutic modalities in the SLE treatment, as seen in
the cancer therapies (44). In the current investigation, we focused on
S1pr1 as a new target of miR-223-3p. In transgenic mice with the
persistent expression of human S1PR1 in lymphocytes, the activated
T cells demonstrated decreased entry into lymph nodes and
increased entry into circulation (45). However, S1PR1 agonists
have been shown to prevent T cell migration from lymph nodesFrontiers in Immunology | www.frontiersin.org 8into circulation and result in amelioration of the clinical features of
SLE in model mice (18, 19, 21–23). After phosphorylation by
sphingosine kinases, fingolimod, S1PR1 modulator, functionally
antagonizes S1PR1 expressed on lymphocytes by receptor
internalization and degradation. This process prevents a
functionally normal response to the endogenous S1P gradient,
thereby blocking lymphocytes to egress from secondary lymphoid
organs to the blood and reducing the circulation of autoreactive
lymphocytes (46). Therefore, S1PR1 dysfunction and
overexpression in T cells are hypothesized to be linked to the
pathogenesis of SLE.
In B6-Mir223−/−Faslpr/lpr mice, the population of splenic
S1PR1+CD4+ T cells was significantly increased compared with
B6-Mir223+/+Faslpr/lpr mice and thus S1PR1+CD4+ T cells were
induced by Mir223 deficiency. Although S1pr1 mRNA and
protein expression was not altered in isolated splenic CD4+ T
cells from B6-Mir223−/−Faslpr/lpr mice compared with B6-
Mir223+/+Faslpr/lpr mice, S1PR1+CD4+ T cells were actively
infiltrated into the glomeruli in B6-Mir223−/−Faslpr/lpr mice.
The results suggested that S1PR1+CD4+ T cells induced by
Mir223 deficiency preferentially migrated into spleen and
inflamed kidney tissues. We postulate that Mir223 is a new
therapeutic target in the treatment of SLE by modulating the
expression of S1PR1.
SinceMir223 is highly expressed in granulocytes compared to T
and B cells (24), we should consider the functional roles of Mir223
in various immune-mediated cells in the translational research.
Mir223 is essential for innate immune responses and inflammatory
diseases such as rheumatoid arthritis and inflammatory bowel
disease (IBD) (47, 48). Mir223 is overexpressed in fibroblast-like
synoviocytes, and synovial fluid of the patients with rheumatoid
arthritis and lentivirus-mediated silencing of Mir223 can suppress
collagen-induced arthritis in mice by decreasing macrophage
colony-stimulating factor receptor levels in the synovium (49). Of
interest, in Mir223 deficient mice, granulocyte numbers are
increased, albeit with an abnormal phenotype, and spontaneouslyA B
FIGURE 6 | Glomerulonephritis with infiltration of CD4+S1PR1+ T cells in in B6-Mir223−/−Faslpr/lpr (A) The image of CD4+ cells, CD4+S1PR1+ cells, CD8+ cells and
CD8+S1PR1+ cells in glomerular lesion in B6-Mir223−/−Faslpr/lpr compared to B6-Mir223+/+Faslpr/lpr mice (n = 5 per group). Images are representative of five mice per
group. Bars = 50 µm. (B) The number of CD4+ cells, CD4+S1PR1+ cells, CD8+ cells and CD8+S1PR1+ cells in glomerulus or tubular lesion in B6-Mir223−/−Faslpr/lpr
compared to B6-Mir223+/+Faslpr/lpr mice (n = 5 per group). Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ns, not significant, by Student’s t-test in (B).January 2021 | Volume 11 | Article 616141
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neutrophils (24). Indeed, neutrophil numbers in peripheral blood
tended to be higher in B6-Mir223−/−Faslpr/lpr mice compared to B6-
Mir223+/+Faslpr/lpr mice (Supplementary Figure 2E). Neutrophils
in SLE have abnormal functions like reducing phagocytosis
capabilities and apoptotic pathways and increasing oxidative
activity and NETosis (50). These neutrophils infiltrate into kidney
tissues affected by lupus nephritis (51). Although Mir223 is not
expressed in kidney cells and there were no renal damages in
Mir223 deficient mice (24), Mir223 deficient neutrophils were
hyperactive and assumed to contribute the glomerular injuries in
Mir223−/−Faslpr/lprmice. Overlapping abnormality in neutrophils by
Mir223 deficiency and SLE was thought to be one of the causes of
exacerbation of lupus nephritis in our B6-Mir223−/−Faslpr/lpr mice.
In addition to the roles in the granulocytes, Mir223 has been
known to be functional particularly in CD4+Th17 cells, which
exacerbated the experimental autoimmune uveitis (EAU) by
promoting autoreactive Th17 cell responses by inhibiting
transcription factor FOXO3 expression (52). CD4+Th17 cells
were also shown to be increased in SLE patients and MRL/lpr
mice (53, 54) and they infiltrate into the kidney tissues and
contribute to tissue damage by producing IL-17 and IFN-g (55).
CD4+ T cells also infiltrate in kidney tissues and link to
exacerbation of lupus nephritis (23). We initially hypothesized
that Mir223 deficiency may ameliorate lupus nephritis since
MIR223 is overexpressed in CD4+ T cells in the patients with
relapsing multiple sclerosis and rheumatoid arthritis (9, 56).
However, Mir223 deficiency exacerbated glomerulonephritis in
B6-Mir223−−-Faslpr/lpr mice by facilitating the infiltration of
S1PR1+CD4+ T cells into kidney tissues.
Although the glomerular deposition of C3 was increased in B6-
Mir223−/−Faslpr/lpr mice, there were no differences in the deposition
of IgG (Supplementary Figure 7B). The complement system is
composed of three major arms of activation pathways and plays
protective and pathogenic roles in the development of SLE. The
classical pathway (CP) contributes to the clearance of immune
complexes and apoptotic cells, whereas the alternative pathway
(AP) and lectin pathway (LP) in lupus exacerbates renal
inflammation (57). Activation of LP is initiated by pattern
recognition molecules (PRMs) without antibodies, and they are
composed of mannose-binding lectin (MBL), ficolin, collectin-liver
10 (CL-10), and CL-11 (58). MBL-associated serine proteases-1 and
-2 (MASP-1 and MASP-2) are the enzymatic constituents of the LP
and form a complex with the PRMs. Masp1 knockout lupus-prone
MRL/lpr mice (Masp1/3−/− MRL/lpr mice) lacking both MASP-1
and its splicing isoform MASP-3 demonstrated reduced activation
of LP and AP. In this model, there were no significant differences
in glomerular IgG but significantly reduced glomerular C3
deposition compared to their wild-type littermates (57). In B6-
Mir223−/−Faslpr/lpr mice, we can speculate that the infiltration of
S1PR1+CD4+ T cells may induce the cellular damage of the
glomeruli, the release of damage-associated molecular patterns
(DAMPs) and subsequent activation of LP (59).
There are some limitations in the current investigation. First,
we employed total Mir223 knockout mice for the investigation.
The CD4+ T cell specific Mir223 knockout mice is required toFrontiers in Immunology | www.frontiersin.org 9further confirm the findings observed in this study. In addition,
we compared miRNA and mRNA profiling between B6 and
MRL/lpr in the initial screening of the candidate miRNAs
(Figure 1). MRL/MpJ mice are the parent and control strain
for MRL/lpr, but we did not compare the expression of Mir223
and S1pr1 between these strains. The genetic background B6/lpr
and MRL/lpr also influenced the phenotype of the Mir223
knockout mice. However, all other functional gene knockout
studies were performed under identical genetic backgrounds
such as B6 or MRL/lpr. Second, we did not employ S1PR1
antagonist to confirm the relationship between S1pr1 and
Mir223. S1PR1-5 antagonist (FTY720/fingolimod) is approved
for multiple sclerosis (60), while selective S1PR1 antagonist
(cenerimod) is currently under phase 2 clinical study (NCT-
02472795) in the patients with SLE. Cenerimod has been
reported to ameliorate systemic and organ-specific pathology
and inflammation in MRL/lpr mice (61), and the administration
of cenerimod intoMir223−/−Faslpr/lpr mice should be investigated
in future studies.
In conclusion, we presented that the deletion of Mir223
exacerbated the lupus phenotypes associated with increased
population of S1PR1+CD4+ T cells and their enhanced
infiltration in inflamed kidney tissues. In addition to the
modulation of the function of S1PR1, Mir223 may be a
valid therapeutic modality in the treatment of SLE by
targeting S1PR1+CD4+ T cells. We believe that the current
investigation provides novel data pertaining to the T cell
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